Tirzepatide is the active ingredient in Mounjaro and Zepbound, and it is one of the most heavily restricted compounds on Meta. If your tirzepatide ads have been banned, you are dealing with pharmaceutical advertising restrictions combined with weight loss claim scrutiny.
We have guided several compounding pharmacies through getting tirzepatide ads approved on Meta. The compound is unique because it is both a prescription drug and a weight loss medication, triggering multiple restriction categories simultaneously.
Why Tirzepatide Ads Get Banned
Meta bans tirzepatide ads because the compound is classified as a prescription GLP-1/GIP drug. Any mention of tirzepatide, Mounjaro, or Zepbound triggers pharmaceutical advertising restrictions. The weight loss association adds another layer of scrutiny.
Common ban triggers include weight loss testimonials, dosage or administration references, mentions of A1C improvement, and pricing for compounded tirzepatide on landing pages.
Regulatory Standards for Tirzepatide Advertising
FDA 503A allows compounding pharmacies to prepare tirzepatide for individual patients with a prescription. Your ads must emphasize the service model, not the drug product. You cannot claim compounded tirzepatide is equivalent to branded Mounjaro or Zepbound.
FDA 503B applies if your facility compounds tirzepatide at scale. Advertising restrictions are similar but include additional requirements for sterility documentation.
The BAV appeal pathway is your route to get banned ads reviewed. Meta requires verified business documentation for tirzepatide-related advertising.
Our Strategy for Tirzepatide Ads
Remove all drug name references. Do not use tirzepatide, Mounjaro, or Zepbound in ad copy. Use GLP-1/GIP therapy consultation or compounding pharmacy services instead.
Eliminate weight loss claims. Do not reference weight loss outcomes, body transformation, or before-and-after results. Focus on consultation availability for patients exploring therapeutic options.
Rebuild your landing page. Add FDA 503A disclaimers, a clear consultation process, and language clarifying your products are compounded per individual prescriptions. Remove pricing for specific medications.
Complete BAV verification. Submit pharmacy license, business registration, and liability insurance documentation before appealing.
Case Study: Tirzepatide Campaign Approval
A compounding pharmacy specializing in tirzepatide had 12 ads banned in one week. Their ads featured weight loss statistics and mentioned Mounjaro by name. We stripped all drug references and outcome claims, rewrote the copy to focus on consultation availability, added FDA 503A compliance language, and completed BAV verification. After resubmission, all ads were approved within 5 days. The campaign achieved a 3x return on ad spend in its first 30 days.
Continue reading
Semaglutide Ads Banned on Facebook
Ready to run these ads? Book a call at calendly.com/custodio-2/30min